Epinephrine Auto-Injectors Cost $600+ and Expire Yearly, Pricing Out Families

A two-pack of brand-name EpiPen auto-injectors carries a list price exceeding $600 in the United States. Generic alternatives (Teva, authorized generic) range from $150-$400, but even these prices are prohibitive for uninsured or underinsured families. The devices expire after 12-18 months regardless of whether they are used, meaning a family with one allergic child must spend $300-$600 every single year on a medication they hope to never need. Families are typically advised to keep multiple sets (home, school, car, grandparents' house), multiplying the annual cost to $1,000-$2,500. This is not an abstract affordability concern. A 2017 study published in the Annals of Allergy, Asthma & Immunology found that one in three families reported not filling or delaying filling an epinephrine prescription due to cost. When families ration or skip epinephrine, children die. Anaphylaxis kills approximately 150-200 Americans per year, and delayed or absent epinephrine administration is the primary modifiable risk factor in nearly every fatal case. The price inflation is well-documented. When Mylan acquired the EpiPen brand in 2007, the list price was approximately $94 for a two-pack. By 2016, it had risen to over $600 — a 500% increase over nine years with no change to the drug (epinephrine itself costs less than $1 per dose) or the delivery device. The Congressional investigation in 2016 found that Mylan's pricing strategy was designed to maximize revenue from a captive market: patients with life-threatening allergies have no choice but to buy the product. The problem persists structurally because of three interlocking factors. First, the auto-injector market has limited competition; only a handful of devices are FDA-approved, and new entrants face years of regulatory process. Second, pharmacy benefit managers (PBMs) negotiate rebates that reduce the net price to insurers but do not reduce the out-of-pocket cost for patients on high-deductible plans. Third, the 12-18 month expiration date is based on potency studies showing degradation over time, but research from the Journal of Allergy and Clinical Immunology suggests that expired auto-injectors retain 80-90% potency for years — a fact not reflected in labeling or insurance coverage. The root cause is a U.S. pharmaceutical pricing system that allows manufacturers of essential, no-substitute medications to set prices without negotiation, while the regulatory barriers to competition (FDA device approval timelines, patent protections on delivery mechanisms) ensure the captive market stays captive.